CCL26 and breast cancer: Tudoran et al. [36] analyzed the gene expression of 84 inflammatory molecules and their receptors, including the chemokines CXCL13 and CCL26 in 40 peripheral blood samples from patients with Her2-primary BC to study the association of triple-negative phenotype with age, clinical stage, tumor size, lymph nodes, and menopausal status.